# Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

> **NCT01896856** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 118 (actual)

## Conditions studied

- Previously Treated Metastatic Colorectal Cancer

## Interventions

- **DRUG:** SGI-110 Dose Escalation
- **DRUG:** Regorafenib
- **DRUG:** TAS-102
- **DRUG:** SGI-110
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01896856
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-23
- **Primary completion:** 2019-08-26
- **Final completion:** 2019-08-26
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2020-10-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896856, "Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01896856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*